Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

NCT03709082 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped Low accrual

Conditions

HER2-positive Breast Cancer
Breast Cancer Metastatic

Interventions

DRUG: Palbociclib 75mg
DRUG: Letrozole 2.5mg
DRUG: T-DM1
DRUG: Palbociclib 100mg
DRUG: Palbociclib 125mg
DRUG: Palbociclib

Sponsor

University of Kansas Medical Center

Collaborators

[object Object]